Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems

OJ L 157, 9.6.2006, p. 1–7 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, SK, SL, FI, SV)
This document has been published in a special edition(s) (BG, RO, HR)

OJ L 157, 9.6.2006, p. 1–7

Case T-6/21: Action brought on 7 January 2021 — Advanced Organic Materials v EUIPO — Swiss Pharma International (ADVASTEROL)

OJ C 62, 22.2.2021, p. 47–48 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 62, 22.2.2021, p. 47–48

Case T-860/19: Judgment of the General Court of 16 December 2020 — Alkemie Group v EUIPO — Mann & Schröder (ALKEMIE) (EU trade mark — Opposition proceedings — Application for EU figurative mark ALKEMIE — Earlier EU word mark Alkmene — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

OJ C 53, 15.2.2021, p. 38–38 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 53, 15.2.2021, p. 38–38

Case T-859/19: Judgment of the General Court of 16 December 2020 — Alkemie Group v EUIPO — Mann & Schröder (ALKEMIE) (EU trade mark — Opposition proceedings — Application for EU word mark ALKEMIE — Earlier EU word mark Alkmene — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

OJ C 53, 15.2.2021, p. 37–37 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 53, 15.2.2021, p. 37–37

Prior notification of a concentration (Case M.10141 — Sanacorp Pharmahandel/Leopold Fiebig and Gerda Nückel) (Text with EEA relevance) 2021/C 47/08

PUB/2021/108

OJ C 47, 10.2.2021, p. 10–11 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 47, 10.2.2021, p. 10–11

Case T-715/20: Action brought on 4 December 2020 — Degode v EUIPO — Leo Pharma (Skinovea)

OJ C 35, 1.2.2021, p. 57–58 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 35, 1.2.2021, p. 57–58

Case C-455/18 P: Appeal brought on 12 July 2018 by Oliver Spieker against the order of the General Court (Seventh Chamber) delivered on 8 May 2018 in Case T-92/18, Oliver Spieker v European Union Intellectual Property Office

OJ C 35, 1.2.2021, p. 18–18 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 35, 1.2.2021, p. 18–18

Case T-792/19: Order of the General Court of 4 December 2020 — Agepha Pharma v EUIPO — Apogepha Arzneimittel (AGEPHA) (EU trade mark — Opposition proceedings — Withdrawal of the opposition — No need to adjudicate)

OJ C 35, 1.2.2021, p. 50–51 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 35, 1.2.2021, p. 50–51

Case T-190/20: Judgment of the General Court of 9 December 2020 — Almea v EUIPO — Sanacorp Pharmahandel (Almea) (EU trade mark — Opposition proceedings — Application for EU figurative mark Almea — Earlier national word mark MEA — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001))

OJ C 35, 1.2.2021, p. 49–49 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 35, 1.2.2021, p. 49–49

Case C-400/20 P: Appeal brought on 21 August 2020 by Dermavita Co. Ltd against the judgment of the General Court (Third Chamber) delivered on 25 June 2020 in Case T-104/19, Dermavita v EUIPO — Allergan Holdings France (JUVÉDERM)

OJ C 35, 1.2.2021, p. 21–22 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

OJ C 35, 1.2.2021, p. 21–22